Solid Tumor Antigens

Cat. No.

AT1162

RG-6125

RG-6125 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CDH11, also known as Cadherin-11. This antibody is comprised of a human IgG2 type heavy chain and a human kappa (huκ) type light chain, exhibiting a predicted molecular weight of 145 kDa. For experimental control purposes, Human IgG2 kappa, Isotype Control is recommended.

Cat. No.

AT1167

CAS No.

2014343-04-3

Imaprelimab

Synonyms: PRX-003

Imaprelimab (PRX-003) is a humanized IgG1κ monoclonal antibody targeting the melanoma cell adhesion molecule (MCAM). Classified as an antineoplastic agent, it is designed to interfere with MCAM-mediated processes, potentially inhibiting tumor growth and metastasis in melanoma and other cancers expressing MCAM. This antibody is utilized primarily in research focused on cancer biology and therapeutic development.

Cat. No.

AT1170

CAS No.

2930861-48-4

Clesitamig

Clesitamig is a humanized antibody designed to specifically target DLL3 (Delta-like ligand 3). This antibody features a variable light chain (V-κ) and a gamma 1 heavy chain (G4CH1-G1h-H-γ1), configured in a structurally optimized format to ensure high specificity and affinity for DLL3. Clesitamig is ideal for research focused on the role of DLL3 in cancer pathogenesis and therapy, particularly in the context of small cell lung cancer and other neuroendocrine tumors where DLL3 expression is prevalent.

Cat. No.

AT1172

CAS No.

1796566-95-4

Sacituzumab

Sacituzumab is a humanized IgG1 monoclonal antibody that specifically targets Trophoblast cell surface antigen 2 (TROP2). This antibody binds to the linear epitopes of the TROP2 protein. Although Sacituzumab alone does not exhibit antitumor effects or inhibit the function of TROP2 during tumor metastasis, it serves as a foundational component for the development of antibody-drug conjugates (ADCs). A notable application of Sacituzumab is its conjugation with the cytotoxic drug, govitecan, to form Sacituzumab govitecan. This conjugate has demonstrated utility in the treatment of triple-negative breast cancer, highlighting its significant potential in therapeutic applications targeting this challenging oncological condition.

Cat. No.

AT1173

Citatuzumab

Citatuzumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target EpCAM (Epithelial Cell Adhesion Molecule), also known as TROP1 or CD326. This antibody comprises a human IgG1 type heavy chain and a human kappa (huκ) type light chain, with a predicted molecular weight of 145.4 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. Citatuzumab is applicable in research focused on cancer cell biology, particularly in studies investigating epithelial cell adhesion and metastasis.

Cat. No.

AT1201

CAS No.

1874157-95-5

Tebentafusp

Synonyms: IMCgp100

Tebentafusp (IMCgp100) is a bispecific fusion protein designed to specifically target the gp100 peptide-HLA-A*02:01 complex, an antigen commonly associated with melanoma. This innovative therapeutic agent employs a dual-action mechanism: it features a high-affinity T-cell receptor (TCR) binding domain that recognizes and binds to gp100-expressing tumor cells, coupled with an anti-CD3 T-cell engaging domain that recruits and activates T cells. Upon engagement, Tebentafusp mediates the production of inflammatory cytokines and cytolytic proteins, culminating in the direct lysis of tumor cells. This targeted approach not only enhances the specificity of T-cell mediated tumor cell killing but also minimizes off-target effects, making it a promising candidate for melanoma therapy.

Cat. No.

AT1213

CAS No.

1615697-16-9

Lifastuzumab

Lifastuzumab is a humanized monoclonal antibody of the IgG1 subtype, targeting the sodium-dependent phosphate transport protein 2b (NaPi2b). This antibody can be conjugated to monomethyl auristatin E (MMAE) via an ADC linker, creating the antibody-drug conjugate lifastuzumab vedotin (DNIB0600A). The resulting conjugate exhibits potent anticancer activity, making it a valuable tool for targeted cancer therapy research.

Cat. No.

AT1224

Anti-CEACAM5/CEA/CD66e Antibody

Cat. No.

AT1291

CAS No.

2853518-94-0

Rinatabart

Rinatabart is a human monoclonal antibody of the IgG1κ subtype designed to target FOLR1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control. This specificity makes Rinatabart suitable for research focused on the biological pathways and diseases associated with the FOLR1 receptor.

Cat. No.

AT1297

Anti-CDH1/E-cadherin/CD324 Antibody

The Anti-CDH1/E-cadherin/CD324 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It is designed to specifically target CDH1, also known as E-cadherin or CD324, a critical protein involved in cell-cell adhesion and cancer metastasis regulation. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 146.6 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is applicable for use in various immunodetection techniques to study E-cadherin expression in pathological samples or in research focused on epithelial cell biology and oncology.

Cat. No.

AT1300

CAS No.

1105038-73-0

Abituzumab

Synonyms: EMD 525797; DI17E6

Abituzumab (DI17E6) is a humanized monoclonal antibody of the IgG2 subtype that targets integrin αV. It effectively inhibits the phosphorylation of focal adhesion kinase (FAK), Akt, and extracellular signal-regulated kinase (ERK), key signaling molecules involved in cell migration and survival. This antibody is particularly useful in cancer research applications, with a focus on studies related to prostate cancer. Abituzumab's precise targeting of integrin αV makes it a valuable tool for investigating the role of this integrin in tumor progression and metastasis.

Cat. No.

AT1302

CAS No.

2888594-15-6

Donitabart

Donitabart is a chimeric humanized antibody of the IgG1κ subtype that specifically targets ganglioside GD2. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Cat. No.

AT1303

CAS No.

2109731-10-2

Tilogotamab

Synonyms: HexaBody-DR5/DR5; Hx-DR5-01/05

Tilogotamab is an enhanced agonistic formulation composed of two antibodies, each targeting distinct epitopes on death receptor type 5 (DR5). This specific interaction with DR5 facilitates its activation, making Tilogotamab a valuable tool in the study of multiple myeloma (MM). This product is designed for research use, focusing on elucidating the pathways and mechanisms associated with DR5 in multiple myeloma.

Cat. No.

AT1315

CAS No.

1879925-92-4

Naxitamab

Synonyms: Naxitamab-gqgk; Humanized 3F8; Hu3F8

Naxitamab (Hu3F8) is a humanized monoclonal antibody specifically designed to target the disialoganglioside GD2, a glycolipid antigen predominantly expressed on the surface of neuroblastoma, osteosarcoma, and other GD2-positive cancer cells. This antibody is utilized extensively in the research of these cancers, providing a critical tool for studying tumor behavior, progression, and potential therapeutic interventions.

Cat. No.

AT1334

Anti-CEACAM1/3/5/6/8 Antibody (6G5j)

The Anti-CEACAM1/3/5/6/8 Antibody (6G5j) is a chimeric mouse monoclonal antibody of the IgG1 κ isotype, designed to target human CEACAM1, CEACAM3, CEACAM5, CEACAM6, and CEACAM8. This antibody enables precise identification and quantification of these carcinoembryonic antigen-related cell adhesion molecules, which are significant in various cellular processes including angiogenesis, apoptosis, and cell signaling. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control in conjunction with this antibody.

Cat. No.

AT1369

Anti-CEACAM5 Antibody (4H11-8)

Anti-CEACAM5 Antibody (4H11-8) is a chimeric mouse monoclonal antibody of the IgG1 κ isotype, specifically designed to target human CEACAM5. For optimal experimental control, it is recommended to use Mouse IgG1 kappa, Isotype Control as the isotype control for this antibody.

Cat. No.

AT1373

CAS No.

1954758-84-9

Anetumab

Synonyms: Anti-MSLN Antibody

Anetumab is a monoclonal antibody specifically targeting mesothelin (MSLN), a well-recognized tumor-associated antigen prevalent in various malignant tumors. This antibody serves as a foundational component in the synthesis of Anetumab ravtansine, an antibody-drug conjugate (ADC) that selectively delivers cytotoxic agents to MSLN-expressing tumor cells. Anetumab is primarily utilized in research settings to investigate the therapeutic potential and targeting efficacy against mesothelin-positive malignancies.

Cat. No.

AT1419

KRN-330

KRN-330 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target GPA33, a cell surface antigen predominantly expressed in colorectal cancer cells. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control, is recommended.

Cat. No.

AT1426

CAS No.

3011830-62-6

Daretabart

Daretabart is a humanized IgG1 kappa monoclonal antibody specifically targeting GD2, a disialoganglioside prevalent on tumor cells. This antibody is designed for use in anti-tumor research to elucidate the role of GD2 in cancer progression and potential therapeutic interventions. The appropriate isotype control for Daretabart is Human IgG1 kappa Isotype Control, which is essential for validating the specificity and ensuring the accuracy of experimental results involving this antibody.

Cat. No.

AT1436

CAS No.

189261-10-7

Natalizumab

Natalizumab is a recombinant, humanized IgG4 monoclonal antibody that targets α4β1-integrin, effectively inhibiting its interaction with vascular cell adhesion molecule-1 (VCAM-1). This antibody is utilized in the management of relapsing-remitting multiple sclerosis and Crohn's disease. It represents the inaugural targeted therapeutic approach that impedes lymphocyte migration into the central nervous system (CNS), thereby preventing acute demyelinating episodes.

Cat. No.

AT1447

CAS No.

1439902-67-6

STX-100

STX-100 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Integrin αVβ6 (ITGAV & ITGB6). This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145.12 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT1457

CAS No.

896731-82-1

Conatumumab

Synonyms: AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody

Conatumumab (AMG 655) is a human monoclonal agonist antibody targeting human death receptor 5 (DR5, TRAILR2), displaying high affinity with dissociation constants (Kd) of 1 nM for the long form of DR5 and 0.8 nM for the short form. This antibody functions by inducing apoptosis through caspase activation, making it highly relevant for cancer research applications.

Cat. No.

AT1461

CAS No.

2897622-41-0

Ciletatug

Ciletatug is a humanized IgG1κ monoclonal antibody specifically targeting Claudin 18 (CLDN18). For experimental control purposes, Human IgG1 kappa Isotype Control is recommended.

Cat. No.

AT1483

IMC-C103C

Synonyms: RG-6290

IMC-C103C is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting MAGE-A4, a member of the melanoma antigen family. This antibody is comprised of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, exhibiting a predicted molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This specificity and configuration make IMC-C103C an essential tool for research focusing on cancer biology and immunotherapy involving MAGE-A4.

Cat. No.

AT1485

CAS No.

2362015-67-4

MVT-5873

MVT-5873 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Sialyl-Lewis A. This antibody is comprised of a human IgG1 heavy chain and a human lambda light chain, and exhibits a predicted molecular weight of approximately 145.66 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This specificity and configuration make MVT-5873 an essential tool for research focused on the role of Sialyl-Lewis A in various biological processes.